

Jason Karlawish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5688512/publications.pdf>

Version: 2024-02-01

111
papers

9,306
citations

136950

32
h-index

43889

91
g-index

115
all docs

115
docs citations

115
times ranked

10959
citing authors

#	ARTICLE	IF	CITATIONS
1	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
2	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	12.4	588
3	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.8	167
4	Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. <i>Neurology</i> , 2011, 77, 1487-1493.	1.1	113
5	APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. <i>PLoS Medicine</i> , 2017, 14, e1002254.	8.4	110
6	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110
7	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 26.	6.2	106
8	Cognitive Aging. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2121.	7.4	96
9	Alzheimer's disease: The next frontier"Special Report 2017. <i>Alzheimer's and Dementia</i> , 2017, 13, 374-380.	0.8	88
10	Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 276-283.	1.3	86
11	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 57-64.	3.7	71
12	Cognitive, social, and neural determinants of diminished decision-making and financial exploitation risk in aging and dementia: A review and new model. <i>Journal of Elder Abuse and Neglect</i> , 2016, 28, 320-344.	1.1	69
13	Awareness of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2017, 72, 974-985.	3.9	67
14	How redesigning AD clinical trials might increase study partners' willingness to participate. <i>Neurology</i> , 2008, 71, 1883-1888.	1.1	65
15	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. <i>PLoS ONE</i> , 2020, 15, e0229137.	2.5	61
16	The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , 2015, 143, 117-127.	3.8	59
17	The Views of Alzheimer Disease Patients and Their Study Partners on Proxy Consent for Clinical Trial Enrollment. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 240-247.	1.2	55
18	Statin Therapy and Risk of Acute Memory Impairment. <i>JAMA Internal Medicine</i> , 2015, 175, 1399.	5.1	55

#	ARTICLE	IF	CITATIONS
19	Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults. <i>JAMA Neurology</i> , 2018, 75, 44.	9.0	54
20	Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. <i>Neurology</i> , 2015, 84, 1488-1494.	1.1	49
21	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
22	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. <i>Nature Reviews Neurology</i> , 2021, 17, 523-524.	10.1	44
23	A Trial of Financial and Social Incentives to Increase Older Adults's Walking. <i>American Journal of Preventive Medicine</i> , 2017, 52, e123-e130.	3.0	43
24	Supported Decision Making With People at the Margins of Autonomy. <i>American Journal of Bioethics</i> , 2021, 21, 4-18.	0.9	43
25	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.8	42
26	What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public. <i>Alzheimer's and Dementia</i> , 2018, 14, 925-932.	0.8	41
27	The Collaborative Aging Research Using Technology Initiative: An Open, Sharable, Technology-Agnostic Platform for the Research Community. <i>Digital Biomarkers</i> , 2021, 4, 100-118.	4.4	40
28	Ascertaining Subjective Cognitive Decline: A Comparison of Approaches and Evidence for Using an Age-Anchored Reference Group. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S43-S55.	2.6	39
29	Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 568-574.	1.2	38
30	A review of ethical issues in dementia. <i>International Psychogeriatrics</i> , 2015, 27, 1635-1647.	1.0	38
31	GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 515-524.	0.8	38
32	Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias. <i>Alzheimer's and Dementia</i> , 2019, 15, 1107-1114.	0.8	36
33	Ethics of reallocating ventilators in the covid-19 pandemic. <i>BMJ</i> , 2020, 369, m1828.	6.0	36
34	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. <i>Neurobiology of Aging</i> , 2016, 39, 147-153.	3.1	35
35	Identifiable Characteristics and Potentially Malleable Beliefs Predict Stigmatizing Attributions Toward Persons With Alzheimer's Disease Dementia: Results of a Survey of the U.S. General Public. <i>Health Communication</i> , 2018, 33, 264-273.	3.1	35
36	Cognitive Impairment Evaluation and Management. <i>Medical Clinics of North America</i> , 2020, 104, 807-825.	2.5	35

#	ARTICLE	IF	CITATIONS
37	Is the WHO Definition of Health Aging Well? Frameworks for "Health" After Three Score and Ten. American Journal of Public Health, 2019, 109, 1104-1106.	2.7	33
38	International drive to illuminate delirium: A developing public health blueprint for action. Alzheimer's and Dementia, 2020, 16, 711-725.	0.8	31
39	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 101.	6.2	29
40	Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 285-300.	2.4	27
41	Alzheimer's Prevention Initiative Generation Program: Development of an <i>APOE</i> genetic counseling and disclosure process in the context of clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 705-716.	3.7	27
42	Establishing a Framework for Gathering Structural and Social Determinants of Health in Alzheimer's Disease Research Centers. Gerontologist, The, 2022, 62, 694-703.	3.9	25
43	What Latino Puerto Ricans and non-Latinos say when they talk about Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 161-170.	0.8	23
44	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
45	"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimer's and Dementia, 2019, 15, 153-157.	0.8	23
46	Study partners should be required in preclinical Alzheimer's disease trials. Alzheimer's Research and Therapy, 2017, 9, 93.	6.2	22
47	Researchers' perspectives on the role of study partners in dementia research. International Psychogeriatrics, 2014, 26, 1649-1657.	1.0	21
48	Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role. Dementia, 2018, 17, 494-514.	2.0	21
49	The Future Is P-Tau" Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests. JAMA Neurology, 2021, 78, 379.	9.0	21
50	Effectiveness and Ethics of Incentives for Research Participation. JAMA Internal Medicine, 2021, 181, 1479.	5.1	21
51	Preclinical Alzheimer Disease and the Dawn of the Pre-Caregiver. JAMA Neurology, 2019, 76, 631.	9.0	20
52	The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers. Journal of Law, Medicine and Ethics, 2018, 46, 485-498.	0.9	19
53	Cognitive correlates of metamemory in Alzheimer's disease.. Neuropsychology, 2014, 28, 695-705.	1.3	18
54	"That would be dreadful": The ethical, legal, and social challenges of sharing your Alzheimer's disease biomarker and genetic testing results with others. Journal of Law and the Biosciences, 2021, 8, lsab004.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. <i>AJOB Empirical Bioethics</i> , 2016, 7, 106-115.	1.6	16
56	Alive inside. <i>Bioethics</i> , 2020, 34, 295-305.	1.4	16
57	Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker. <i>JAMA Neurology</i> , 2019, 76, 864.	9.0	15
58	Examining the Pathways Between Self-Awareness and Well-Being in Mild to Moderate Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1297-1306.	1.2	13
59	What is paradoxical lucidity? The answer begins with its definition. <i>Alzheimer's and Dementia</i> , 2022, 18, 513-521.	0.8	13
60	Application of In-Home Monitoring Data to Transition Decisions in Continuing Care Retirement Communities: Usability Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e18806.	4.3	13
61	The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , 2022, 292, 114620.	3.8	13
62	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 414-417.	3.9	12
63	Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People Living with Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, S37-S42.	2.6	12
64	Family members' perspectives on learning cognitively unimpaired older adults' amyloidâ€² <sc>PET</sc> scan results. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3203-3211.	2.6	12
65	Parkinsonian signs are a risk factor for falls. <i>Gait and Posture</i> , 2017, 55, 1-5.	1.4	11
66	Disclosing Alzheimer Disease Biomarker Results to Research Participants. <i>JAMA Neurology</i> , 2022, 79, 645.	9.0	11
67	Desktop Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2061-2.	7.4	10
68	Modification of everyday activities and its association with self-awareness in cognitively diverse older adults. <i>PLoS ONE</i> , 2019, 14, e0222769.	2.5	10
69	Participation of persons with dementia and their caregivers in research. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1784-1792.	2.6	10
70	Randomized evaluation of trial acceptability by INcentive (RETAIN): Study protocol for two embedded randomized controlled trials. <i>Contemporary Clinical Trials</i> , 2019, 76, 1-8.	1.8	9
71	Caregiving at a Physical Distance: Initial Thoughts for <sc>COVID</sc>â€¹9 and Beyond. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1170-1172.	2.6	9
72	Research Attitudes Questionnaire scores predict Alzheimerâ€™s disease clinical trial dropout. <i>Clinical Trials</i> , 2021, 18, 237-244.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease. <i>Lancet Psychiatry</i> , 2017, 4, e6-e7.	7.4	8
74	Unfinished Business in Preventing Alzheimer Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1739.	5.1	7
75	Rescuing Research Participants After Alzheimer Trials Stop Early. <i>JAMA Neurology</i> , 2020, 77, 413.	9.0	7
76	Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1015-1028.	2.6	7
77	Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab. <i>Drugs and Aging</i> , 2022, 39, 389-400.	2.7	7
78	Policy statement on voting by persons with dementia residing in long-term care facilities. , 2006, 2, 243-245.		6
79	Identifying an appropriate measurement modeling approach for the Mini-Mental State Examination.. <i>Psychological Assessment</i> , 2016, 28, 125-133.	1.5	5
80	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. <i>Trials</i> , 2017, 18, 474.	1.6	5
81	The Interview for Decisional Abilities (IDA): a tool to assess the decisional capacity of abused and neglected older adults. <i>Journal of Elder Abuse and Neglect</i> , 2019, 31, 244-254.	1.1	5
82	Don't Have Time to Sit and Talk with Them? Hospitalists' Perspectives on Palliative Care Consultation for Patients with Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2365-2372.	2.6	5
83	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. <i>Neurology</i> , 2021, 97, 496-500.	1.1	5
84	Aducanumab and the Business of Alzheimer Disease—Some Choice. <i>JAMA Neurology</i> , 2021, 78, 1303.	9.0	5
85	Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 31-39.	2.2	5
86	Prognosis Communication in Late-Life Disability: A Mixed Methods Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2496-2501.	2.6	4
87	Where Do You End, and I Begin? How Relationships Confound Advance Directives in the Care of Persons Living with Dementia. <i>American Journal of Bioethics</i> , 2020, 20, 83-85.	0.9	4
88	Social Cognition and the Aging Brain. <i>Annals of Internal Medicine</i> , 2019, 170, 726.	3.9	3
89	Together Make a Visit; Together Make a Plan? Messaging to Adult Children with Concerns about a Parent's Memory Loss. <i>Health Communication</i> , 2020, 35, 512-523.	3.1	3
90	The ethical implications of paradoxical lucidity in persons with dementia. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3617-3622.	2.6	3

#	ARTICLE	IF	CITATIONS
91	A Typical Day With Mild Cognitive Impairment. American Journal of Public Health, 2017, 107, 927-928.	2.7	2
92	Is there a difference between terminal lucidity and paradoxical lucidity?. Alzheimer's and Dementia, 2022, 18, 540-541.	0.8	2
93	Predictors of who Serves as an Alzheimer's Disease Research Participant's Study Partner and the Impact of their Relationship on Study Partners' Reports on Participants. Research on Aging, 2022, 44, 734-746.	1.8	2
94	Supported Decision Making with People at the Margins of Autonomy: Response to Commentaries. American Journal of Bioethics, 2022, 22, W1-W4.	0.9	2
95	Unwrapping A Fragile ConceptThe Alzheimer Conundrum By Lock Margaret Princeton (NJ) : Princeton University Press , 2014 328App., \$29.95. Health Affairs, 2014, 33, 718-719.	5.2	1
96	Acute stroke trials without informed consent. Neurology, 2016, 86, 1472-1473.	1.1	1
97	Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum, 2021, 2, e211428.	2.2	1
98	P2-229: WHICH SELF-REPORTED COGNITIVE DIFFICULTIES DIFFERENTIATE COGNITIVELY NORMAL OLDER ADULTS FROM THOSE WITH MCI?. , 2014, 10, P558-P559.		0
99	P4-069: DEVELOPMENT OF A PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS. , 2014, 10, P808-P808.		0
100	Decision-Making Capacity Will Have a Limited Effect on Civil Commitment Practices. American Journal of Bioethics, 2019, 19, 86-88.	0.9	0
101	Desktop Medicine and the Practice of Wealth Care. JAMA Internal Medicine, 2021, 181, 227.	5.1	0
102	Please, Don't Fly Me to the Moon. American Journal of Bioethics, 2021, 21, 20-22.	0.9	0
103	Preliminary results from the COVID caregiving project. Alzheimer's and Dementia, 2021, 17, e055199.	0.8	0
104	How knowledge of elevated amyloid impacts neuropsychological performance in cognitively normal older adults: Findings from the REVEAL SCAN Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
105	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
106	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
107	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
108	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0

#	ARTICLE	IF	CITATIONS
109	Cognitively unimpaired adults's reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
110	Cognitively unimpaired adults's reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
111	A Case of Patient Abandonment, or an Abandonment of Patients?. American Journal of Bioethics, 2022, 22, 86-87.	0.9	0